MDGL Madrigal Pharmaceuticals

Madrigal Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences

Madrigal Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences

CONSHOHOCKEN, Pa., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) today announced that the company will participate in fireside chats at three upcoming investor conferences:

Jefferies Global Healthcare Conference in London

Thursday, Nov. 20, 2025 at 8:30 A.M. GMT (3:30 A.M. ET)

The presentation will be webcast live and may be accessed .

8th Annual Evercore Healthcare Conference

Tuesday, Dec. 2, 2025 at 4:15 P.M. ET

The presentation will be webcast live and may be accessed .

Piper Sandler 37th Annual Healthcare Conference

Wednesday, Dec. 3, 2025 at 1:30 P.M. ET

The presentation will be webcast live and may be accessed .

The fireside chats will be webcast live and can be accessed by visiting Madrigal’s Investor Relations Events .

About Madrigal

Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra is the first and only medication approved by both the FDA and European Commission for the treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c). For more information, visit .

Investor Contact

Tina Ventura,

Media Contact

Christopher Frates,



EN
17/11/2025

Underlying

MDGLMadrigal Pharmaceuticals

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Madrigal Pharmaceuticals

 PRESS RELEASE
Free
MDGL Madrigal Pharma...

Madrigal Pharmaceuticals Announces Participation at Three Upcoming Inv...

Madrigal Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences CONSHOHOCKEN, Pa., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) today announced that the company will participate in fireside chats at three upcoming investor conferences: Jefferies Global Healthcare Conference in LondonThursday, Nov. 20, 2025 at 8:30 A.M. GMT (3:30 A.M. ET)The presentation will be webcast live and may be accessed . 8th Annual Evercore Healthcare ConferenceTuesday, Dec. 2, 2025 at 4:15 P.M. ETThe presentation will be webcast live and may be accessed...

21h / 44m 1 EN
 PRESS RELEASE
Free
MDGL Madrigal Pharma...

Madrigal Presents New Data Demonstrating Rezdiffra® (resmetirom) Signi...

Madrigal Presents New Data Demonstrating Rezdiffra® (resmetirom) Significantly Improved Multiple Noninvasive Imaging Tests and Biomarkers in Patients with Compensated MASH Cirrhosis Rezdiffra® treatment significantly improved liver stiffness, fibrosis biomarkers, and markers of clinically significant portal hypertension risk in patients with compensated MASH cirrhosis Rezdiffra also improved disease-specific quality of life measures in patients with and without cirrhosis, with sustained effect through two years of treatmentNew analysis examining effects of Rezdiffra treatment interruption u...

November 10, 2025 1 EN
 PRESS RELEASE
Free
MDGL Madrigal Pharma...

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under N...

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) CONSHOHOCKEN, Pa., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on November 1, 2025 to 18 new non-executive employees as equity inducement awards under the terms of Madrigal’s 2025 Inducement Plan. The equity awards were approved by Madrigal’s independent Compensation Committee in ac...

November 6, 2025 1 EN
 PRESS RELEASE
Free
MDGL Madrigal Pharma...

Madrigal Pharmaceuticals Reports Third-Quarter 2025 Financial Results ...

Madrigal Pharmaceuticals Reports Third-Quarter 2025 Financial Results and Provides Corporate Updates Third-quarter 2025 Rezdiffra™ (resmetirom) net sales of $287.3 millionAs of September 30, 2025, more than 29,500 patients on Rezdiffra Closed global licensing agreement with CSPC Pharma to add oral GLP-1 to pipeline New Orange Book listed patent for Rezdiffra providing protection into 2045 Launched Rezdiffra in Germany following European Commission approval Reports cash, cash equivalents, restricted cash and marketable securities of $1.1 billion as of Sept. 30, 2025Company to host conference...

November 4, 2025 1 EN
 PRESS RELEASE
Free
MDGL Madrigal Pharma...

Madrigal to Present New Data from the Company’s MASH Program at AASLD’...

Madrigal to Present New Data from the Company’s MASH Program at AASLD’s The Liver Meeting 2025 Two oral presentations to highlight biomarker, imaging and quality-of-life data from the open-label compensated MASH cirrhosis (F4c) arm of the Phase 3 MAESTRO-NAFLD-1 trial of RezdiffraPoster of distinction examines the impact of Rezdiffra interruption on patients, underscoring the need for continued treatment to prevent disease progressionFurther poster presentations examine early real-world experience with Rezdiffra and the clinical burden of MASH CONSHOHOCKEN, Pa., Oct. 28, 2025 (GLOBE NEWS...

October 28, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch